Human papillomavirus testing 2007-2012: Co-testing and triage utilization and impact on subsequent clinical management

Jack Cuzick, Orrin Myers, William C. Hunt, Debbie Saslow, Philip E. Castle, Walter Kinney, Alan Waxman, Michael Robertson, Cosette M. Wheeler

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In the United States, high-risk human papillomavirus (HPV) testing is recommended for women with atypical squamous cells of unknown significance (ASC-US) cytology, and co-testing with cytology and HPV is a recommended option for screening women aged ≥30 years. No population-based data are available to examine utilization of HPV testing in the United States. Using the New Mexico HPV Pap Registry data resource, we describe population trends (2007-2012) in utilization and positivity rates for HPV testing as a routine co-testing screening procedure and for triage of ASC-US and other cytologic outcomes. For women aged 30-65 years co-testing increased from 5.2% in 2007 to 19.1% in 2012 (p-<-0.001). Overall 82% of women with ASC-US cytology who did not receive co-testing also had an HPV test. HPV positivity was age and cytology result dependent but did not show time trends. For women with negative cytology, 64% received an additional screening test within 3 years if no co-test was done or if it was positive, but this was reduced to 47% with a negative co-test. Reflex HPV testing for ASC-US cytology is well established and occurs in most women. Evidence for reflex testing is also observed following other abnormal cytology outcomes. Co-testing in women aged 30-65 years has more than tripled from 2007 to 2012, but was still only used in 19.1% of women aged 30-65 years attending for screening in 2012. Women receiving co-testing had longer repeat screening intervals, but rescreening within 3 years is still very common even with co-testing. What's new? Concurrent testing (co-testing) for cytology and human papillomavirus (HPV) has been recommended for primary cervical-cancer screening since 2002. In this study, the authors found that, although co-testing more than tripled between 2007 and 2012, it still occurs in fewer than 20% of women. On the other hand, 82% of women with ASC-US cytology were then tested for HPV. The registry used in this study (the New Mexico HPV Pap Registry) provides a model for evaluating cervical screening and follow-up outcomes and potentially the model can be translated to other cancers.

Original languageEnglish (US)
Pages (from-to)2854-2863
Number of pages10
JournalInternational Journal of Cancer
Volume136
Issue number12
DOIs
StatePublished - Jun 15 2015
Externally publishedYes

Fingerprint

Triage
Cell Biology
Registries
Reflex
Early Detection of Cancer
Uterine Cervical Neoplasms
Population
Atypical Squamous Cells of the Cervix

Keywords

  • cervical screening
  • coverage
  • high-risk HPV testing
  • HPV co-testing
  • New Mexico
  • New Mexico HPV Pap Registry
  • outcome
  • United States
  • utilization

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Human papillomavirus testing 2007-2012 : Co-testing and triage utilization and impact on subsequent clinical management. / Cuzick, Jack; Myers, Orrin; Hunt, William C.; Saslow, Debbie; Castle, Philip E.; Kinney, Walter; Waxman, Alan; Robertson, Michael; Wheeler, Cosette M.

In: International Journal of Cancer, Vol. 136, No. 12, 15.06.2015, p. 2854-2863.

Research output: Contribution to journalArticle

Cuzick, J, Myers, O, Hunt, WC, Saslow, D, Castle, PE, Kinney, W, Waxman, A, Robertson, M & Wheeler, CM 2015, 'Human papillomavirus testing 2007-2012: Co-testing and triage utilization and impact on subsequent clinical management', International Journal of Cancer, vol. 136, no. 12, pp. 2854-2863. https://doi.org/10.1002/ijc.29337
Cuzick, Jack ; Myers, Orrin ; Hunt, William C. ; Saslow, Debbie ; Castle, Philip E. ; Kinney, Walter ; Waxman, Alan ; Robertson, Michael ; Wheeler, Cosette M. / Human papillomavirus testing 2007-2012 : Co-testing and triage utilization and impact on subsequent clinical management. In: International Journal of Cancer. 2015 ; Vol. 136, No. 12. pp. 2854-2863.
@article{79045f0b19f742068170669093279d95,
title = "Human papillomavirus testing 2007-2012: Co-testing and triage utilization and impact on subsequent clinical management",
abstract = "In the United States, high-risk human papillomavirus (HPV) testing is recommended for women with atypical squamous cells of unknown significance (ASC-US) cytology, and co-testing with cytology and HPV is a recommended option for screening women aged ≥30 years. No population-based data are available to examine utilization of HPV testing in the United States. Using the New Mexico HPV Pap Registry data resource, we describe population trends (2007-2012) in utilization and positivity rates for HPV testing as a routine co-testing screening procedure and for triage of ASC-US and other cytologic outcomes. For women aged 30-65 years co-testing increased from 5.2{\%} in 2007 to 19.1{\%} in 2012 (p-<-0.001). Overall 82{\%} of women with ASC-US cytology who did not receive co-testing also had an HPV test. HPV positivity was age and cytology result dependent but did not show time trends. For women with negative cytology, 64{\%} received an additional screening test within 3 years if no co-test was done or if it was positive, but this was reduced to 47{\%} with a negative co-test. Reflex HPV testing for ASC-US cytology is well established and occurs in most women. Evidence for reflex testing is also observed following other abnormal cytology outcomes. Co-testing in women aged 30-65 years has more than tripled from 2007 to 2012, but was still only used in 19.1{\%} of women aged 30-65 years attending for screening in 2012. Women receiving co-testing had longer repeat screening intervals, but rescreening within 3 years is still very common even with co-testing. What's new? Concurrent testing (co-testing) for cytology and human papillomavirus (HPV) has been recommended for primary cervical-cancer screening since 2002. In this study, the authors found that, although co-testing more than tripled between 2007 and 2012, it still occurs in fewer than 20{\%} of women. On the other hand, 82{\%} of women with ASC-US cytology were then tested for HPV. The registry used in this study (the New Mexico HPV Pap Registry) provides a model for evaluating cervical screening and follow-up outcomes and potentially the model can be translated to other cancers.",
keywords = "cervical screening, coverage, high-risk HPV testing, HPV co-testing, New Mexico, New Mexico HPV Pap Registry, outcome, United States, utilization",
author = "Jack Cuzick and Orrin Myers and Hunt, {William C.} and Debbie Saslow and Castle, {Philip E.} and Walter Kinney and Alan Waxman and Michael Robertson and Wheeler, {Cosette M.}",
year = "2015",
month = "6",
day = "15",
doi = "10.1002/ijc.29337",
language = "English (US)",
volume = "136",
pages = "2854--2863",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Human papillomavirus testing 2007-2012

T2 - Co-testing and triage utilization and impact on subsequent clinical management

AU - Cuzick, Jack

AU - Myers, Orrin

AU - Hunt, William C.

AU - Saslow, Debbie

AU - Castle, Philip E.

AU - Kinney, Walter

AU - Waxman, Alan

AU - Robertson, Michael

AU - Wheeler, Cosette M.

PY - 2015/6/15

Y1 - 2015/6/15

N2 - In the United States, high-risk human papillomavirus (HPV) testing is recommended for women with atypical squamous cells of unknown significance (ASC-US) cytology, and co-testing with cytology and HPV is a recommended option for screening women aged ≥30 years. No population-based data are available to examine utilization of HPV testing in the United States. Using the New Mexico HPV Pap Registry data resource, we describe population trends (2007-2012) in utilization and positivity rates for HPV testing as a routine co-testing screening procedure and for triage of ASC-US and other cytologic outcomes. For women aged 30-65 years co-testing increased from 5.2% in 2007 to 19.1% in 2012 (p-<-0.001). Overall 82% of women with ASC-US cytology who did not receive co-testing also had an HPV test. HPV positivity was age and cytology result dependent but did not show time trends. For women with negative cytology, 64% received an additional screening test within 3 years if no co-test was done or if it was positive, but this was reduced to 47% with a negative co-test. Reflex HPV testing for ASC-US cytology is well established and occurs in most women. Evidence for reflex testing is also observed following other abnormal cytology outcomes. Co-testing in women aged 30-65 years has more than tripled from 2007 to 2012, but was still only used in 19.1% of women aged 30-65 years attending for screening in 2012. Women receiving co-testing had longer repeat screening intervals, but rescreening within 3 years is still very common even with co-testing. What's new? Concurrent testing (co-testing) for cytology and human papillomavirus (HPV) has been recommended for primary cervical-cancer screening since 2002. In this study, the authors found that, although co-testing more than tripled between 2007 and 2012, it still occurs in fewer than 20% of women. On the other hand, 82% of women with ASC-US cytology were then tested for HPV. The registry used in this study (the New Mexico HPV Pap Registry) provides a model for evaluating cervical screening and follow-up outcomes and potentially the model can be translated to other cancers.

AB - In the United States, high-risk human papillomavirus (HPV) testing is recommended for women with atypical squamous cells of unknown significance (ASC-US) cytology, and co-testing with cytology and HPV is a recommended option for screening women aged ≥30 years. No population-based data are available to examine utilization of HPV testing in the United States. Using the New Mexico HPV Pap Registry data resource, we describe population trends (2007-2012) in utilization and positivity rates for HPV testing as a routine co-testing screening procedure and for triage of ASC-US and other cytologic outcomes. For women aged 30-65 years co-testing increased from 5.2% in 2007 to 19.1% in 2012 (p-<-0.001). Overall 82% of women with ASC-US cytology who did not receive co-testing also had an HPV test. HPV positivity was age and cytology result dependent but did not show time trends. For women with negative cytology, 64% received an additional screening test within 3 years if no co-test was done or if it was positive, but this was reduced to 47% with a negative co-test. Reflex HPV testing for ASC-US cytology is well established and occurs in most women. Evidence for reflex testing is also observed following other abnormal cytology outcomes. Co-testing in women aged 30-65 years has more than tripled from 2007 to 2012, but was still only used in 19.1% of women aged 30-65 years attending for screening in 2012. Women receiving co-testing had longer repeat screening intervals, but rescreening within 3 years is still very common even with co-testing. What's new? Concurrent testing (co-testing) for cytology and human papillomavirus (HPV) has been recommended for primary cervical-cancer screening since 2002. In this study, the authors found that, although co-testing more than tripled between 2007 and 2012, it still occurs in fewer than 20% of women. On the other hand, 82% of women with ASC-US cytology were then tested for HPV. The registry used in this study (the New Mexico HPV Pap Registry) provides a model for evaluating cervical screening and follow-up outcomes and potentially the model can be translated to other cancers.

KW - cervical screening

KW - coverage

KW - high-risk HPV testing

KW - HPV co-testing

KW - New Mexico

KW - New Mexico HPV Pap Registry

KW - outcome

KW - United States

KW - utilization

UR - http://www.scopus.com/inward/record.url?scp=84927577410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927577410&partnerID=8YFLogxK

U2 - 10.1002/ijc.29337

DO - 10.1002/ijc.29337

M3 - Article

C2 - 25447979

AN - SCOPUS:84927577410

VL - 136

SP - 2854

EP - 2863

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -